S
Steven P. Margossian
Researcher at Dana Corporation
Publications - 50
Citations - 1793
Steven P. Margossian is an academic researcher from Dana Corporation. The author has contributed to research in topics: Transplantation & Internal medicine. The author has an hindex of 17, co-authored 41 publications receiving 1313 citations. Previous affiliations of Steven P. Margossian include Harvard University & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Cdk5rap2 regulates centrosome function and chromosome segregation in neuronal progenitors
Sofia B. Lizarraga,Steven P. Margossian,Steven P. Margossian,Marian H. Harris,Marian H. Harris,Dean R. Campagna,An-Ping Han,Sherika Blevins,Raksha Mudbhary,Jane E. Barker,Christopher A. Walsh,Mark D. Fleming +11 more
TL;DR: The findings suggest that the reduction in brain size observed in humans with mutations in CDK5RAP2 is associated with impaired centrosomal function and with changes in mitotic spindle orientation during progenitor proliferation.
Journal ArticleDOI
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Marcelo C. Pasquini,Zhen-Huan Hu,Kevin J. Curran,Theodore W. Laetsch,Frederick L. Locke,Rayne H. Rouce,Michael A. Pulsipher,Christine L Phillips,Amy K. Keating,Matthew J. Frigault,Dana Salzberg,Samantha Jaglowski,Joshua P. Sasine,Joseph Rosenthal,Monalisa Ghosh,Daniel J. Landsburg,Steven P. Margossian,Paul L. Martin,Manali Kamdar,Peiman Hematti,Sarah Nikiforow,Cameron J. Turtle,Miguel-Angel Perales,Patricia Steinert,Mary M. Horowitz,Amy Moskop,Lida Bubuteishvili Pacaud,Lan Yi,Raghav Chawla,Eric Bleickardt,Stephan A. Grupp,Stephan A. Grupp +31 more
TL;DR: This first report of tisagenlecleucel in the real-world setting demonstrates outcomes with similar efficacy and improved safety compared with those seen in the pivotal trials.
Journal ArticleDOI
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J Curran,Kevin J Curran,Steven P. Margossian,Steven P. Margossian,Nancy A. Kernan,Nancy A. Kernan,Lewis B. Silverman,Lewis B. Silverman,David A. Williams,David A. Williams,Neerav Shukla,Rachel Kobos,Christopher J. Forlenza,Peter G. Steinherz,Peter G. Steinherz,Susan E. Prockop,Susan E. Prockop,Farid Boulad,Farid Boulad,Barbara Spitzer,Barbara Spitzer,Maria Cancio,Maria Cancio,Jaap Jan Boelens,Andrew L. Kung,Yasmin Khakoo,Yasmin Khakoo,Victoria Szenes,Jae H. Park,Craig S. Sauter,Glenn Heller,Xiuyan Wang,Brigitte Senechal,Richard J. O'Reilly,Isabelle Riviere,Michel Sadelain,Renier J. Brentjens +36 more
TL;DR: The data supports the safety of CD19-specific CAR T cell therapy for R/R B-ALL and suggest that dose intensity of conditioning chemotherapy and minimal pre-treatment disease burden have a positive impact on response without a negative effect on toxicity.
Journal ArticleDOI
Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin.
Rocío Montes de Oca,Rocío Montes de Oca,Rocío Montes de Oca,Paul R. Andreassen,Paul R. Andreassen,Paul R. Andreassen,Steven P. Margossian,Steven P. Margossian,Steven P. Margossian,Richard C. Gregory,Richard C. Gregory,Richard C. Gregory,Toshiyasu Taniguchi,Toshiyasu Taniguchi,Toshiyasu Taniguchi,Xiao Zhe Wang,Xiao Zhe Wang,Xiao Zhe Wang,Scott Houghtaling,Scott Houghtaling,Scott Houghtaling,Markus Grompe,Markus Grompe,Markus Grompe,Alan D. D'Andrea,Alan D. D'Andrea,Alan D. D'Andrea +26 more
TL;DR: The results indicate that monoubiquitination of FANCD2 regulates chromatin binding and that D1428 within the carboxy terminal acidic sequence encoded by exon 44 is independently required for functional complementation of FA-D2 cells.
Journal ArticleDOI
Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance.
TL;DR: Two novel DNA damage-inducible phosphorylation sites on FANCD2, threonine 691 and serine 717 are identified and support a role for the FA pathway in the coordination of the S phase of the cell cycle.